Online

ESTRO EORTC OligoCare Workshop

30 June (16:00-19:00 CEST) and 1 July (16:00-17:30 CEST) | Workshop leaders: M. Guckenberger (CH) and P. Ost (BE)
  • Participants will learn about the current clinical status and recent scientific developments in the field of Oligo-Metastatic Disease
  • Participants will learn how to optimise follow-up and data capture in OligoCare
  • Participants will learn about challenging cases treated with SBRT for Oligo-Metastatic Disease
  • Workshop is open to centres participating in OligoCare
  • Radiation oncologists with a clinical and research focus on SBRT and Oligo-Metastatic Disease
  • Medical physicists
  • Radiobiologists with an interest in radiotherapy for metastatic disease

The workshop is free of charge.

30th June: Please click here to register. The link to attend the online workshop is sent to the email address that you specified during the registration process.

1st July: The workshop on July 1st is open to OligoCare cohort participating centres only. Please click here to register. The link to attend the online workshop is sent to the email address that you specified during the registration process.

 

Programme 30 June from 16:00-19:00 CEST

 

Time slot

Title

Speaker

16:00-16:05

Welcome

M. Guckenberger (CH) and P. Ost (BE)

16:05-16:25

Keynote lecture: Past, present and future of OMD, focus on patient identification and biomarker research

Ralph Weichselbaum (US)

16:25-16:45

Will imaging with single-cell resolution improve oligometastatic patient selection in the future?

Guillem Pratx (US)

16:45-17:05

Randomised trials in clinical OMD research: needed and realistic?

David Palma (CA)

17:05-17:25

Added value of registry trials to advance OMD research: the UK experience

Nicholas van As (UK)

17:25-17:30

Break

 

17:30-17:50

Challenges of radiotherapy treatment planning for “multiple” oligometastases

Coen Hurkmans (NL)

17:50-18:10

Radical radiotherapy beyond OMD: results from ImmunoSABR trials

Willemijn Theelen (NL)

18:10-18:30

Keynote lecture: Will better systemic therapy increase or decrease the need for local treatment in (oligo-) metastatic disease?

Rolf Stahel (CH)

18:30-19:00

Roundtable with industry representatives

 

 

Programme 1 July from 16:00-17:30 CEST (open to participating centres only)

 

Time slot

Title

Speaker

16:00-16:30

Overview of the current status and preliminary results of OligoCare

M. Guckenberger (CH)

16:30-16:45

Case discussion: the challenging OMD case I

P. Ost (BE)

16:45-17:00

Optimising data quality

EORTC

17:00-17:10

The secret of successful recruitment in OligoCare

Recruiting Centre

17:10-17:25

Case discussion: the challenging OMD case II

Recruiting Centre

17:25-17:30

Closing remarks: Optimising patient follow-up

All